Helius Medical Technologies, Inc. (NASDAQ:HSDT) Short Interest Up 100.8% in October

Helius Medical Technologies, Inc. (NASDAQ:HSDT) saw a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 118,900 shares, an increase of 100.8% from the September 30th total of 59,200 shares. Based on an average trading volume of 434,700 shares, the short-interest ratio is currently 0.3 days.

Helius Medical Technologies Stock Performance

Helius Medical Technologies stock traded down $0.05 during mid-day trading on Monday, reaching $0.44. 43,006 shares of the company were exchanged, compared to its average volume of 375,687. Helius Medical Technologies has a 12-month low of $0.37 and a 12-month high of $9.50. The firm has a market cap of $1.59 million, a P/E ratio of -0.05 and a beta of 1.60. The business has a fifty day moving average of $0.68 and a 200 day moving average of $1.36.

Helius Medical Technologies (NASDAQ:HSDT) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.14). Helius Medical Technologies had a negative return on equity of 258.06% and a negative net margin of 1,487.54%. The business had revenue of $0.18 million for the quarter. During the same period last year, the firm earned ($3.00) earnings per share.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Helius Medical Technologies stock. Armistice Capital LLC acquired a new stake in shares of Helius Medical Technologies, Inc. (NASDAQ:HSDT) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 130,000 shares of the company’s stock, valued at approximately $127,000. Armistice Capital LLC owned about 4.39% of Helius Medical Technologies as of its most recent SEC filing. 18.63% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Maxim Group reissued a “hold” rating on shares of Helius Medical Technologies in a report on Wednesday, October 16th.

About Helius Medical Technologies

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.